Sleep behavior traits and associations with opioid-related adverse events: a cohort study

Rudy W Chen,Ma Cherrysse Ulsa,Peng Li,Chenlu Gao,Xi Zheng,Jiawei Xu,Yong Luo,Shiqian Shen,Jacqueline Lane,Frank A J L Scheer,Kun Hu,Lei Gao
DOI: https://doi.org/10.1093/sleep/zsad118
IF: 6.313
2023-04-19
SLEEP
Abstract:Abstract Study Objectives Opioid-related adverse events (OAEs), including opioid use disorders, overdose, and death, are serious public health concerns. OAEs are often associated with disrupted sleep, but the long-term relationship between poor sleep and subsequent OAE risk remains unknown. This study investigates whether sleep behavior traits are associated with incident OAEs in a large population cohort. Methods 444,039 participants (mean age±SD 57±8years) from the UK Biobank reported their sleep behavior traits (sleep duration, daytime sleepiness, insomnia-like complaints, napping, and chronotype) between 2006-2010. The frequency/severity of these traits determined a poor sleep behavior burden score (0-9). Incident OAEs were obtained from hospitalization records during 12-year median follow-up. Cox proportional hazards models examined the association between sleep and OAEs. Results Short and long sleep duration, frequent daytime sleepiness, insomnia symptoms, and napping, but not chronotype, were associated with increased OAE risk in fully adjusted models. Compared to the minimal poor sleep behavior burden group (scores of 0-1), the moderate (4-5) and significant (6-9) groups had hazard ratios of 1.47 (95% confidence interval [1.27, 1.71]), p < 0.001, and 2.19 ([1.82, 2.64], p < 0.001), respectively. The latter risk magnitude is greater than the risk associated with pre-existing psychiatric illness or sedative-hypnotic medication use. In participants with moderate/significant poor sleep burden (vs. minimal), subgroup analysis revealed that age <65 years was associated with a higher OAE risk than in those ≥65 years. Conclusion Certain sleep behavior traits and overall poor sleep burden are associated with an increased risk for opioid-related adverse events.
neurosciences,clinical neurology
What problem does this paper attempt to address?